eplerenon of - αποτελεσματα

arrotex pharmaceuticals pty ltd - eplerenone, quantity: 25 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; croscarmellose sodium; magnesium stearate; iron oxide yellow; microcrystalline cellulose; iron oxide red; purified talc; lactose monohydrate; macrogol 6000 - eplerenone is indicated to reduce the risk of: - cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3?14 days of an acute myocardial infarction (see clinical trials and dosage and administration). - cardiovascular mortality and morbidity in adult patients with nyha class ii (chronic) heart failure and left ventricular systolic dysfunction (lvef ? 30% or lvef ? 35% in addition to qrs duration of > 130 msec), in addition to standard optimal therapy (see clinical trials).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eplerenone-dwrn eplerenone 50 mg tablet blister pack

arrotex pharmaceuticals pty ltd - eplerenone, quantity: 50 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; iron oxide yellow; titanium dioxide; lactose monohydrate; macrogol 6000; hypromellose; purified talc; magnesium stearate; iron oxide red - eplerenone is indicated to reduce the risk of: - cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3?14 days of an acute myocardial infarction (see clinical trials and dosage and administration). - cardiovascular mortality and morbidity in adult patients with nyha class ii (chronic) heart failure and left ventricular systolic dysfunction (lvef ? 30% or lvef ? 35% in addition to qrs duration of > 130 msec), in addition to standard optimal therapy (see clinical trials).